Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats
<p>Abstract</p> <p>Objectives</p> <p>Endothelial dysfunction precedes atherogenesis and clinical complications in type 2 diabetes. The vascular dysfunction in Zucker diabetic fatty (ZDF) rats was evaluated at different ages along with the effect of treatment with rosigl...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2010-05-01
|
| Series: | Cardiovascular Diabetology |
| Online Access: | http://www.cardiab.com/content/9/1/19 |
| _version_ | 1818381197787529216 |
|---|---|
| author | Onyia Jude E Zimmerman Karen M Karathanasis Sotirios K Guo Xiaomei Lu Xiao Peterson Richard G Kassab Ghassan S |
| author_facet | Onyia Jude E Zimmerman Karen M Karathanasis Sotirios K Guo Xiaomei Lu Xiao Peterson Richard G Kassab Ghassan S |
| author_sort | Onyia Jude E |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Objectives</p> <p>Endothelial dysfunction precedes atherogenesis and clinical complications in type 2 diabetes. The vascular dysfunction in Zucker diabetic fatty (ZDF) rats was evaluated at different ages along with the effect of treatment with rosiglitazone (Rosi) on endothelial function and mechanical remodeling.</p> <p>Methods</p> <p>The Rosi treatment was given to ZDF rats for 3 weeks. The endothelium-dependent vasodilation and α-adrenoceptor-dependent vasoconstriction of femoral arteries were studied using an <it>ex-vivo </it>isovolumic myograph. The biomechanical passive property of the arteries was studied in Ca<sup>2+</sup>-free condition. The expressions of endothelial nitric oxide synthase (eNOS), α-adrenoceptor, matrix metalloproteinase 9 (MMP9), and elastase were evaluated.</p> <p>Results</p> <p>Endothelium-dependent vasorelaxation of the femoral artery was blunted at low doses in ZDF rats at 11 weeks of age and attenuated at all doses in ZDF rats at 19 weeks of age. The expression of eNOS was consistent with the endothelium-dependent vasorelaxation. The α-adrenoceptor was activated and the mechanical elastic modulus was increased in ZDF rats at 19 weeks of age. The expressions of α-adrenoceptor, MMP9, and elastase were up regulated in ZDF rats at 19 weeks of age. Rosi treatment for 3 weeks restored endothelium-dependent vasorelaxation and the expression of eNOS and the adrenoceptor activation at the doses below 10<sup>-6 </sup>mole/L in ZDF rats at 19 weeks of age. Rosi treatment for 3 weeks did not, however, improve the mechanical properties of blood vessel, the expressions of α-adrenoceptor, MMP9, and elastase in ZDF rats.</p> <p>Conclusion</p> <p>The endothelial dysfunction and mechanical remodeling are observed as early as 19 weeks of age in ZDF rat. Rosi treatment for 3 weeks improves endothelial function but not mechanical properties.</p> |
| first_indexed | 2024-12-14T02:30:45Z |
| format | Article |
| id | doaj.art-1d23eb2f2152452081085071b834b771 |
| institution | Directory Open Access Journal |
| issn | 1475-2840 |
| language | English |
| last_indexed | 2024-12-14T02:30:45Z |
| publishDate | 2010-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Cardiovascular Diabetology |
| spelling | doaj.art-1d23eb2f2152452081085071b834b7712022-12-21T23:20:15ZengBMCCardiovascular Diabetology1475-28402010-05-01911910.1186/1475-2840-9-19Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty ratsOnyia Jude EZimmerman Karen MKarathanasis Sotirios KGuo XiaomeiLu XiaoPeterson Richard GKassab Ghassan S<p>Abstract</p> <p>Objectives</p> <p>Endothelial dysfunction precedes atherogenesis and clinical complications in type 2 diabetes. The vascular dysfunction in Zucker diabetic fatty (ZDF) rats was evaluated at different ages along with the effect of treatment with rosiglitazone (Rosi) on endothelial function and mechanical remodeling.</p> <p>Methods</p> <p>The Rosi treatment was given to ZDF rats for 3 weeks. The endothelium-dependent vasodilation and α-adrenoceptor-dependent vasoconstriction of femoral arteries were studied using an <it>ex-vivo </it>isovolumic myograph. The biomechanical passive property of the arteries was studied in Ca<sup>2+</sup>-free condition. The expressions of endothelial nitric oxide synthase (eNOS), α-adrenoceptor, matrix metalloproteinase 9 (MMP9), and elastase were evaluated.</p> <p>Results</p> <p>Endothelium-dependent vasorelaxation of the femoral artery was blunted at low doses in ZDF rats at 11 weeks of age and attenuated at all doses in ZDF rats at 19 weeks of age. The expression of eNOS was consistent with the endothelium-dependent vasorelaxation. The α-adrenoceptor was activated and the mechanical elastic modulus was increased in ZDF rats at 19 weeks of age. The expressions of α-adrenoceptor, MMP9, and elastase were up regulated in ZDF rats at 19 weeks of age. Rosi treatment for 3 weeks restored endothelium-dependent vasorelaxation and the expression of eNOS and the adrenoceptor activation at the doses below 10<sup>-6 </sup>mole/L in ZDF rats at 19 weeks of age. Rosi treatment for 3 weeks did not, however, improve the mechanical properties of blood vessel, the expressions of α-adrenoceptor, MMP9, and elastase in ZDF rats.</p> <p>Conclusion</p> <p>The endothelial dysfunction and mechanical remodeling are observed as early as 19 weeks of age in ZDF rat. Rosi treatment for 3 weeks improves endothelial function but not mechanical properties.</p>http://www.cardiab.com/content/9/1/19 |
| spellingShingle | Onyia Jude E Zimmerman Karen M Karathanasis Sotirios K Guo Xiaomei Lu Xiao Peterson Richard G Kassab Ghassan S Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats Cardiovascular Diabetology |
| title | Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats |
| title_full | Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats |
| title_fullStr | Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats |
| title_full_unstemmed | Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats |
| title_short | Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats |
| title_sort | rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in zucker diabetic fatty rats |
| url | http://www.cardiab.com/content/9/1/19 |
| work_keys_str_mv | AT onyiajudee rosiglitazonereversesendothelialdysfunctionbutnotremodelingoffemoralarteryinzuckerdiabeticfattyrats AT zimmermankarenm rosiglitazonereversesendothelialdysfunctionbutnotremodelingoffemoralarteryinzuckerdiabeticfattyrats AT karathanasissotiriosk rosiglitazonereversesendothelialdysfunctionbutnotremodelingoffemoralarteryinzuckerdiabeticfattyrats AT guoxiaomei rosiglitazonereversesendothelialdysfunctionbutnotremodelingoffemoralarteryinzuckerdiabeticfattyrats AT luxiao rosiglitazonereversesendothelialdysfunctionbutnotremodelingoffemoralarteryinzuckerdiabeticfattyrats AT petersonrichardg rosiglitazonereversesendothelialdysfunctionbutnotremodelingoffemoralarteryinzuckerdiabeticfattyrats AT kassabghassans rosiglitazonereversesendothelialdysfunctionbutnotremodelingoffemoralarteryinzuckerdiabeticfattyrats |